Value and level of plasma homocysteine in patients with angina pectoris undergoing coronary angiographic study

International Heart Journal

Volumn 52, Issue 5, 2011, Pages 280-285

  Chai, Han Tan ^a   Chen, Yung Lung ^a   Chung, Sheng Ying ^a   Tsai, Tzu Hsien ^a   Yang, Cheng Hsu ^a   Chen, Huang Chung ^a   Sung, Pei Hsun ^a   Sun, Cheuk Kwan ^b   Chang, Li Teh ^c   Fan, Chang Qing ^d   Yip, Hon Kan ^a  

^a University College of Medicine   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c MEIHO UNIVERSITY   (Taiwan)

^d Xiamen Chang Gung Memorial Hospital   (China)

Author keywords

Angina pectoris; Coronary artery disease; Long term clinical outcome; Plasma tHcy level

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; HOMOCYSTEINE;

ADULT; AGE; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE VESSEL CORONARY ARTERY DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; ANGINA PECTORIS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY OCCLUSION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 80054792236     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.280     Document Type: Article

References (38)

1. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97: 596-601. (Review)
2. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950-1999: the Framingham Heart Study. Circulation 2004; 110: 522-7.
3. Grover SA, Coupal L, Hu X P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274: 801-6.
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
5. Ridker PM, Rifai N, Pfeffer MA, et al. Infammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-44.
6. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-6.
7. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e) ine and cardiovascular disease: a critical review of epidemiologic evidence. Ann Intern Med 1999; 131: 363-75. (Review)
8. Hulthe J, McPheat W, Samnegård A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006; 188: 450-4.
9. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
10. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 1139-47.
11. Burke A P, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002; 105: 2019-23.
12. Yip HK, Sun CK, Chang LT, Wu CJ. Strong correlation between serum levels of infammatory mediators and their distribution in infarct coronary artery. Circ J 2006; 70: 838-45.
13. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol 2010; 26: 41A-44A. (Review)
14. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. Arch Intern Med 1998; 158: 1301-6. (Review)
15. Medina MA, Amores-Sánchez MI. Homocysteine: an emergent cardiovascular risk factor? Eur J Clin Invest 2000; 30: 754-62. (Review)
16. Knekt P, Reunanen A, Alfthan G, et al. Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med 2001; 161: 1589-94.
17. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-79. (Review)
18. Chua S, Wu CJ, Chang HW, et al. Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention. Int Heart J 2005; 46: 181-93.
19. Hermiller JB, Cusma JT, Spero LA, Fortin DF, Harding MB, Bashore TM. Quantitative and qualitative coronary angiographic analysis: review of methods, utility, and limitations. Cathet Cardio-vasc Diagn 1992; 25: 110-31. (Review)
20. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229-32.
21. Schnyder G, Roff M, Flammer Y, Pin R, Hess OM. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 2002; 23: 726-33.
22. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-80.
23. Kark JD, Selhub J, Adler B, et al. Nonfasting plasma total homo-cysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med 1999; 131: 321-30.
24. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefa-nadis C. Homocysteine and coronary atherosclerosis: from folate fortifcation to the recent clinical trials. Eur Heart J 2009; 30: 6-15. (Review)
25. Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homo-cysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defned coronary artery disease. Circulation 2000; 102: 1227-32.
26. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homo-cysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-10.
27. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
28. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 1989; 114: 473-501. (Review)
29. García-Tevijano ER, Berasain C, Rodríguez JA, et al. Hyperho-mocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fbrosis. Hypertension 2001; 38: 1217-21.
30. Kaye JM, Stanton KG, McCann VJ, et al. Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic patients. Clin Sci (Lond) 2002; 102: 631-7.
31. Stein JH, Bushara M, Bushara K, McBride PE, Jorenby DE, Fiore MC. Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels. Clin Cardiol 2002; 25: 23-6.
32. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteine-mia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506-11.
33. Pitla S, Nagalla B. Gender-related differences in the relationship between plasma homocysteine, anthropometric and conventional biochemical coronary heart disease risk factors in middle-aged Indians. Ann Nutr Metab 2009; 54: 1-6.
34. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
35. Gaede P, Vedel P, Larsen N, Jensen G V, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
36. Vittinghoff E, Shlipak MG, Varosy PD, et al. Risk factors and secondary prevention in women with heart disease: the Heart and Es-trogen/progestin Replacement Study. Ann Intern Med 2003; 138: 81-9.
37. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39. (Review)
38. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation 2009; 119: 3078-84.